Loading the company…
Loading the company…
Families: Thrombectomy, IVC filters & venous stents, Aneurysm & intracranial embolization, Tumor & fibroid embolization, Peripheral arterial intervention.
All companies · Product and company coverage
In the last ten years FDA made 19 decisions for Penumbra (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 4 procedure families, the most in 2018 (4). The latest was on 2026-06-10.
In 2025, Penumbra reported engagement with 7,575 surgeons and other clinicians in the states MedaRep covers, worth $6.6M in consulting, speaking, meals and travel for its device products, the most in Florida ($1.1M to 1,043). Royalties are left out.
| Penumbra System (Reperfusion Catheter RED 43) |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Penumbra.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Florida ($1.1M, 1,043 engaged), California ($697K, 672 engaged), Texas ($597K, 579 engaged), New York ($503K, 446 engaged), North Carolina ($304K, 149 engaged).